Search Results

You searched for : pembrolizumab  

	How the Immune System is Transforming Cancer Treatment Immunotherapy is a drug used in the treatment of cancer. It is a new modality of treatment. immunotherapy is given intravenously (injection) usually at 2 ... Jun 30
	How Targeted Therapy & Immunotherapy Are Transforming Lymphoma Care Cancer is a serious global health issue, and specialists are constantly exploring for more effective and less hazardous treatment options.... Sep 15
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 Antibody As the ZM008-001 clinical trial progresses, the medical community eagerly awaits the results, which could lead the way for a new era in cancer ... Jun 13
	Evaxion Biotech announces Clinical Collaboration to evaluate Keytruda in melanoma patients Latest news updates... Oct 26
	Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106 Latest Pharma Update... Aug 23
	Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. ... Jul 12
	M2GEN announces new collaboration with Merck to advance Cancer therapies Another pharma collaboration for the advancement of cancer therapies ... Mar 22
	BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors BioInvent and Transgene, today announced they have received regulatory approval in Belgium for a clinical trial application (CTA) for a Phase l/lla study of ... Dec 21
	KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival ... Dec 16
	KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma... Nov 10
	BriaCell announces the overall breast cancer survival (OS) data of its lead product candidate, Bria-IMT™ Median OS of 13.3 months has been observed in the Phase I/IIa study for patients treated with Bria-IMT™ in combination with immune ... Oct 21
	PharmAbcine entered into a strategic partnership with Samsung Biologic PharmAbcine is a clinical-stage biotech company developing fully human therapeutic antibodies to treat cancer and neovascular disease... Sep 22
	PharmAbcine signs a CMO contract with Binex for Olinvacimab production Binex will produce olinvacimab at its new 5,000L production line... Sep 03
	Merck’s KEYTRUDA Receives Two New Approvals in Japan Keytruda would be soon launched in Japan for the treatment of cancerous tumors... Aug 27
	Singapore cancer drug ETC-159 advances further in clinical trials First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours ... Jul 31
	PharmAbcine signs manufacturing agreement with Binex PharmAbcine signs long-term contract manufacturing organization agreement for Olinvacimab with Binex ... Jun 27
	Merck Innovates Breakthrough in Cancer Care Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 ... May 14
	IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8th ... Sep 13
	Three-Year Survival Update: Pembrolizumab Effective as First-Line Therapy for Advanced Non-Small Cell Lung Cancer First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy, according to data presented today by Dr. M. Reck, Lung Clinic ... Sep 10
19 Matching result(s) found!

Trending Now
	The Value of Risk Communication in Public HealthOctober 08, 2026
	What Makes a Reliable Health Screening Programme?October 08, 2026
	How Language Access Can Improve Patient Communication in Indian HealthcareOctober 07, 2026
	Why Health Literacy Matters in Preventive HealthcareOctober 07, 2026
	Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
	Improving Follow-Up After Diagnostic Testing: Where Systems Commonly Break DownOctober 07, 2026
	How Community Health Workers Support Preventive Care DeliveryOctober 07, 2026
	AI in India's Emergency Departments: Reducing Diagnostic DelaysOctober 06, 2026
	AI and Patient Consent in India: Who Is Responsible?October 06, 2026
	Wearable Technology in Pregnancy: Benefits and LimitsOctober 06, 2026
	Remote Monitoring for High-Risk Pregnancies in IndiaOctober 06, 2026
	Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
	Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
	Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
	Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
	Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
	Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
	Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
	The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
	Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026